Frank Mathias

Frank Mathias currently works at Oxford Biomedica Plc, as Chief Executive Officer & Director from 2023, OXB US, Inc., as Chief Executive Officer, August Faller GmbH & Co. KG, as Chairman-Supervisory Board, Vfa Bio, as Chairman, ArcticZymes Technologies ASA, as Chairman from 2024, Seqens SAS, as Director, Rentschler Biopharma SE, as Member-Supervisory Board from 2023, LEUKOCARE AG, as Member-Supervisory Board, Mediatum GmbH, as Member-Supervisory Board, leon-nanodrugs GmbH, as Member-Supervisory Board, and Rentschler Biotechnologie Beteiligungs GmbH, as Member-Supervisory Board.
Dr. Mathias also formerly worked at AMGEN GmbH, as Chief Executive Officer, Dr. Rentschler Holding GmbH & Co. KG, as Chief Executive Officer, Catherex, Inc., as Director, Hoechst AG, as Manager-International Product, MediGene AG, as Member-Executive Board in 2016, Servier Deutschland GmbH, as General Manager, and MediGene AG, as Independent Member-Supervisory Board.
Dr. Mathias received his doctorate degree in 1991 from Université Pierre et Marie Curie.